In tumor diseases, SPP1 can activate PI3K/AKT and FAK pathways, drive epithelial mesenchymal transition, induce MDSC proliferation, and inhibit CD8 + T cell activity (45, 46); in autoimmune diseases, SPP1 leads to local inflammatory cell infiltration (47, 48). Here, PTK2 is linked to autoimmune disease.